A recent analysis of data from a clinical trial involving older adults has revealed higher rates of brain bleeding among those who took daily low-dose aspirin, with no significant protection against stroke. The analysis, published in the medical journal JAMA, highlights that low-dose aspirin may not be suitable for individuals without a history of heart conditions or stroke warning signs. The study suggests that older adults who are prone to falls, which can result in brain bleeds, should exercise caution when considering aspirin use. These findings support the recommendations of the U.S. Preventive Services Task Force, which stated that low-dose aspirin should not be prescribed for the prevention of first heart attacks or strokes in healthy older adults.
Dr. Randall Stafford, a medical professor and epidemiologist at Stanford University who was not involved in the study, emphatically states that healthy individuals without multiple risk factors for heart disease should not start taking aspirin. However, he acknowledges that the decision becomes more complex for individuals who do not fit into this category. For those who have already experienced a heart attack or stroke, daily aspirin is still considered an important part of their care by many cardiac and stroke experts.
The analysis used data from a large clinical trial called Aspirin in Reducing Events in the Elderly (ASPREE), which examined the effects of daily low-dose aspirin on older adults in Australia and the United States. The trial included 19,114 participants over the age of 70 who did not have any symptomatic cardiovascular disease. The aim was to uncover the nuances of aspirin’s risk-benefit balance in older patients, given the increased likelihood of clot-related strokes and head trauma from falls in this population.
The study randomly assigned participants to either a group taking daily 100 milligram doses of aspirin or a group taking a placebo. The researchers followed the participants for an average of 4.7 years. While aspirin seemed to reduce the occurrence of clot-related strokes, the reduction was not statistically significant. However, the analysis did find a significant increase of 38 percent in intracranial bleeding among those taking daily aspirin compared to those taking placebo. This rigorous study design, which involved manual review of medical records by specialists, was lauded by cardiologists who were not involved in the study.
Despite the study’s strengths, some cardiologists question how its findings can be applied to the diverse population of the United States, as the majority of participants were from Australia and 91 percent of them were white. Nevertheless, recent studies have shown that aspirin’s protective power against future heart attacks and strokes is limited, and its use can lead to dangerous side effects.
Last year, the U.S. Preventive Services Task Force recommended that individuals who have never experienced a heart attack or stroke should not start taking low-dose aspirin due to the risk of internal bleeding. However, some stroke patients have misunderstood this guidance and have abruptly stopped taking aspirin, only to end up in the emergency room with a second stroke. It is crucial for patients to consult with a doctor before stopping aspirin use.
Dr. Shlee S. Song, director of the Comprehensive Stroke and Telestroke Programs at Cedars-Sinai, stresses the importance of considering how well one fits into the study’s population before making any decisions. She emphasizes that individuals who have had a heart attack or stroke should not be influenced by this study’s findings and should continue taking aspirin as recommended.
Dr. Joshua Willey, a stroke specialist at Columbia University, explains that the risk-benefit calculation for each patient will vary, depending on factors such as how long they have been on aspirin and why their doctor initially recommended it. For patients who need to remain on aspirin, the study’s findings hold different significance for doctors. They should prioritize measures to mitigate the risk of falls, such as checking the patient’s balance, providing physical therapy, and ensuring a safe home environment.
In conclusion, the analysis of data from the ASPREE trial reinforces the caution against using low-dose aspirin for the prevention of heart attacks and strokes in healthy older adults. While the study has limitations, it highlights the need for individualized risk-benefit assessments when considering aspirin use. It is crucial for patients to consult with their doctors and discuss their specific circumstances before making any decisions regarding aspirin therapy.
Denial of responsibility! VigourTimes is an automatic aggregator of Global media. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, and all materials to their authors. For any complaint, please reach us at – [email protected]. We will take necessary action within 24 hours.
